ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference [Canadian Business Journal (Canada)]
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference [Financial Post (Toronto, Ontario, Canada)]
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference